My Treatment Approach: Metastatic Triple-Negative Breast Cancer

Expert oncologists center discussion on a clinical scenario to highlight optimal treatment strategies in metastatic triple-negative breast cancer.

EP. 1: Perspectives on the Current Treatment Landscape of TNBC

July 18th 2022

Expert oncologists share insight on the prognosis of triple-negative breast cancer (TNBC) and broadly review current treatment options for patients.

EP. 2: Clinical Scenario: mTNBC Treated With Chemotherapy Then Sacituzumab Govitecan

July 18th 2022

After reviewing a patient scenario of relapsed/refractory metastatic TNBC, expert oncologists elucidate use of sacituzumab govitecan in this setting.

EP. 3: Metastatic TNBC: Safety, Efficacy, and Quality of Life With Sacituzumab Govitecan

July 25th 2022

Comprehensive discussion on the safety and efficacy profile of the antibody-drug conjugate (ADC) sacituzumab govitecan and managing ADC-related adverse events in patients with mTNBC.

EP. 4: Novel ADCs Under Investigation in Triple-Negative Breast Cancer

July 25th 2022

Expert oncologists review novel ADCs in TNBC and consider how their approval may impact sequencing of therapy in this setting.

EP. 5: Addressing Unmet Needs in the Management of TNBC

August 2nd 2022

Perspectives on the most prominent unmet needs in metastatic triple-negative breast cancer and how these may be addressed with future clinical trials.

EP. 6: Practical Advice on the Management of TNBC

August 2nd 2022

Before closing out their conversation on metastatic triple-negative breast cancer, expert oncologists share a few clinical pearls on optimizing TNBC management.